OPKO Health, Inc. (NASDAQ:OPK) Files An 8-K Results of Operations and Financial ConditionItem 2.02.
On March1, 2018, OPKO Health, Inc., a Delaware corporation (the “Company”), held a conference call to provide a business update and discuss its operating and financial highlights for the quarter and full year ended December31, 2017, which included revenue guidance for the first quarter of 2018. A copy of the conference call transcript is being furnished herewith as Exhibit 99.1.
The information included herein and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934 as amended (“Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 as amended (the “Securities Act”) or the Exchange Act, except as expressly set forth by specific reference in such a filing.
| Item 2.02. | Regulation FD Disclosure. |
The disclosure contained in Item 2.02 of this Current Report on Form 8-K is incorporated by reference into this Item 2.02.
The information included herein and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing.
| Item 2.02. | Financial Statements and Exhibits. |
(d) Exhibits
Opko Health, Inc. ExhibitEX-99.1 2 d527936dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Client Id: 77 THOMSON REUTERS STREETEVENTS PRELIMINARY TRANSCRIPT OPK—Q4 2017 OPKO Health Inc Earnings Call EVENT DATE/TIME: MARCH 01,…To view the full exhibit click here
About OPKO Health, Inc. (NASDAQ:OPK)
OPKO Health, Inc. (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations. The Company’s diagnostics business includes Bio-Reference Laboratories (Bio-Reference), which is a clinical laboratory with a genetic testing business, including the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. Its pharmaceutical business includes OPKO Biologics, which features hGH-CTP, a once-weekly human growth hormone injection (in Phase III and partnered with Pfizer), and a longer acting Factor VIIa drug for hemophilia (Phase IIa). In addition to its pharmaceutical and diagnostic development programs, it owns pharmaceutical platforms in Ireland, Chile, Spain and Mexico.
